Orthocell Delivers Record Revenue as Global Commercial Expansion Accelerates
Orthocell Limited (ASX: OCC) reported record financial and commercial performance for the June 2026 quarter, highlighting strong global momentum for its regenerative medicine portfolio. Quarterly revenue reached a record AU$3.8 million, up 20% from the previous quarter and 36% higher than the corresponding period last year, while FY2026 revenue climbed 44% to a record AU$13.2 million. Growth was driven by rising adoption of Remplir™ in Australia, increasing surgeon and hospital uptake in the United States, and expanding international distribution.
The company strengthened its financial position with AU$44.1 million in available funds, supporting ongoing commercialisation and manufacturing expansion without requiring additional capital. During the quarter, Orthocell expanded U.S. hospital access, secured new regulatory approvals for Striate+™ in Colombia and Ecuador, progressed Remplir’s UK and European regulatory pathway, and broadened humanitarian initiatives in Ukraine. The company also continued advancing new clinical applications, reinforcing its strategy to expand market opportunities and accelerate long-term global growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Orthocell Delivers Record Revenue as Global Commercial Expansion Accelerates
Orthocell Limited (ASX: OCC) reported record financial and commercial performance for the June 2026 quarter, highlighting strong global momentum for its regenerative medicine portfolio. Quarterly revenue reached a record AU$3.8 million, up 20% from the previous quarter and 36% higher than the corresponding period last year, while FY2026 revenue climbed 44% to a record AU$13.2 million. Growth was driven by rising adoption of Remplir™ in Australia, increasing surgeon and hospital uptake in the United States, and expanding international distribution.
The company strengthened its financial position with AU$44.1 million in available funds, supporting ongoing commercialisation and manufacturing expansion without requiring additional capital. During the quarter, Orthocell expanded U.S. hospital access, secured new regulatory approvals for Striate+™ in Colombia and Ecuador, progressed Remplir’s UK and European regulatory pathway, and broadened humanitarian initiatives in Ukraine. The company also continued advancing new clinical applications, reinforcing its strategy to expand market opportunities and accelerate long-term global growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au